ClinicaliQ Trial Snapshot
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) — Active Not Recruiting • Phase III • Oncology • NCT05629585.
- TROPION-Breast03 Summary.
- New cancer drug Dato-DXd, with or without immunotherapy, tested against standard treatment in triple-negative breast cancer patients with remaining disease after chemotherapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy. Conditions: Breast Cancer Interventions: Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab Lead Sponsor: AstraZeneca Planned Enrollment: 1174 participants